Skip to content

Aldeyra on go with mid-stage study of ADX-629 in COVID-19

September 9, 2020

Aldeyra Therapeutics (NASDAQ:ALDX) announces that the FDA has signed off on a 30-subject Phase 2 clinical trial evaluating ADX-629 in hospitalized adult COVID-19 patients.

Participants will be enrolled upon hospitalization for the respiratory illness and will receive ADX-629 or placebo twice per day for up to 28 days (on top of standard of care treatment). Key objectives include the NIAID COVID-19 scale and levels of cytokines and and reactive aldehyde species (RASP).

ADX-629 is an orally available RASP inhibitor that works upstream to modulate the immune system from a pro-inflammatory state to an anti-inflammatory state.

Mid-stage studies in psoriasis and atopic asthma should launch next quarter.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: